The Department of Health and Human Services, through the National Institutes of Health (NIH), has released a funding opportunity titled "Artificial Intelligence in Pre-clinical Drug Development for AD/ADRD (R01 Clinical Trial Not Allowed)." This initiative invites applications to utilize artificial intelligence (AI) and machine learning (ML) techniques to enhance drug discovery for Alzheimer's disease (AD) and related dementias. The goal is to expedite the identification and optimization of preclinical drug candidates, while increasing their chances of success in clinical trials. The NIH plans to invest $6 million for 3-4 awards, with applications capped at $1 million in direct costs per year over a maximum of five years. Eligible applicants include higher education institutions, non-profits, for-profit entities, and foreign organizations. Key dates include an application opening date of January 13, 2025, and a closing date of February 14, 2025. The initiative emphasizes the development of open-source analytical tools and the importance of collaboration between academic institutions and biotech/pharma companies to tackle the complexities of drug discovery. Applications focused on in vitro chemical probes, virtual compound screening, and integrating AI/ML with molecular data are of particular interest, while those proposing clinical trials will not be accepted.